浙江海正生物材料股份有限公司信息披露暂缓与豁免管理办法 浙江海正生物材料股份有限公司 第五条 公司拟披露的信息涉及商业秘密或者保密商务信息（以下统称商业秘密）， 符合下列情形之一，且尚未公开或者泄露的，可以暂缓或者豁免披露： （一）属于核心技术信息等，披露后可能引致不正当竞争的； （二）属于公司自身经营信息，客户、供应商等他人经营信息，披露后可能侵犯公司、 他人商业秘密或者严重损害公司、他人利益的； 信息披露暂缓与豁免管理办法 第一章 总则 第一条 为规范浙江海正生物材料股份有限公司（以下简称"公司"、"本公司"） 信息披露暂缓与豁免行为，确保本公司及相关信息披露义务人依法合规履行信息披露义务， 保护投资者合法权益，根据《上海证券交易所科创板股票上市规则》（以下简称《股票上 市规则》）、《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》（以 下简称《规范运作指引》）、《上市公司信息披露暂缓与豁免管理规定》和《公司章程》 等规定，特制定本办法。 第二条 公司暂缓、豁免披露临时报告，在定期报告、临时报告中豁免披露中国证券 监督管理委员会（以下简称"中国证监会"）和上海证券交易所规定或者要求披露的内 ...

浙江海正生物材料股份有限公司内部控制评价管理制度 浙江海正生物材料股份有限公司 内部控制评价管理制度 第一章 总则 第一条 目的：为规范浙江海正生物材料股份有限公司（以下简称 "公司"）内部 控制评价工作，规范内部控制评价程序和评价报告，揭示和防范风险，根据证监会、财 政部等五部委下发的《企业内部控制基本规范》、《企业内部控制评价指引》等有关法 律、法规的规定，并结合本公司实际情况，制定本制度。 第二条 适用范围：适用于浙江海正生物材料股份有限公司及其子公司。 第二章 管理职责 第五条 董事会负责公司内部控制评价的管理，对内部控制评价报告的真实性负责 并批准内部控制评价报告。 第三条 定义：本制度所称内部控制评价（以下可简称"内控评价"），是指公司 董事会对内部控制的有效性进行全面评价、形成评价结论、出具评价报告的过程。 第四条 管理原则 1、全面性原则。评价工作应当包括内部控制的设计与运行，涵盖公司及其所属单 位的各种业务和事项。 2、重要性原则。评价工作应当在全面评价的基础上，关注重要业务单位、重大业 务事项和高风险领域。 3、客观性原则。评价工作应当准确地揭示经营管理的风险状况，如实反映内部控 制设计与 ...

浙江海正生物材料股份有限公司募集资金管理制度 浙江海正生物材料股份有限公司 募集资金管理制度 第一章 总则 第一条 为规范浙江海正生物材料股份有限公司（以下简称"公司"）募集 资金的使用和管理，提高募集资金的使用效率，根据《中华人民共和国公司法》 《中华人民共和国证券法》《上市公司募集资金监管规则》《上海证券交易所科 创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第1号—规 范运作》等法律、行政法规、规范性文件及《浙江海正生物材料股份有限公司章 程》（以下简称"公司章程"）的规定，结合公司实际情况，制定本制度。 第二条 本制度所指"募集资金"是指公司通过发行股票或者其他具有股权 性质的证券，向投资者募集并用于特定用途的资金，但不包括公司为实施股权激 励计划募集的资金。 第三条 公司董事会应当持续关注募集资金存放、管理和使用情况，有效防 范投资风险，提高募集资金使用效益。 公司的董事和高级管理人员应当勤勉尽责，确保公司募集资金安全，不得操 控上市公司擅自或者变相改变募集资金用途。 第四条 公司控股股东、实际控制人及其他关联人不得直接或者间接占用或 者挪用公司募集资金，不得利用公司募集资金及募集资金 ...

浙江海正生物材料股份有限公司金融衍生品交易管理制度 第一章 总 则 第一条 为规范浙江海正生物材料股份有限公司（以下简称"公司"）及下属子公司 金融衍生品交易业务及相关信息披露工作，加强对金融衍生品交易业务的管理，防范相关 交易风险，健全和完善公司金融衍生品交易业务管理机制，根据《中华人民共和国公司法》 《中华人民共和国证券法》《上海证券交易所科创板股票上市规则》《上海证券交易所上 市公司自律监管指引第5号——交易与关联交易》《上海证券交易所科创板上市公司自律 监管指引第1号——规范运作》及《浙江海正生物材料股份有限公司章程》（以下简称"《公 司章程》"）等有关规定，结合公司实际情况，特制定本制度。 第二条 本制度所称的金融衍生品交易业务主要包括外汇远期、外汇掉期、外汇期权、 结构性远期、利率互换、利率掉期、利率期权、货币互换等。 第三条 本制度适用于本公司及各子公司的金融衍生品交易业务，但未经公司同意， 公司各子公司不得操作该业务。 浙江海正生物材料股份有限公司 金融衍生品交易管理制度 第二章 金融衍生品交易业务的基本原则 第四条 公司进行金融衍生品交易业务遵循合法、谨慎、安全和有效的原则，不进行 单纯以盈 ...

浙江海正生物材料股份有限公司董事会议事规则 公司设董事会，对股东会负责。董事会制定董事会议事规则，以确保董事会落实 股东会决议，提高工作效率，保证科学决策。 第二条 董事会日常事务处理 董事会下设证券部，处理董事会日常事务。 董事会秘书兼任证券部负责人，董事会秘书可以指定证券事务代表等有关人员 协助其处理日常事务。 第三条 定期会议 董事会会议分为定期会议和临时会议。 浙江海正生物材料股份有限公司 董事会议事规则 第一条 宗旨 为进一步规范浙江海正生物材料股份有限公司（以下简称"公司"）董事会的议事 方式和决策程序，促使董事和董事会有效地履行其职责，提高董事会规范运作和科学 决策水平，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）、《上市公司治理准则》《上海证券交易所科创 板股票上市规则》（以下简称"《股票上市规则》"）、《浙江海正生物材料股份有限公 司章程》（以下简称"《公司章程》"）等相关法律法规的规定，结合公司实际情况， 制订本规则。 董事会每年应当至少在上下两个半年度各召开一次定期会议。 第四条 定期会议的提案 在发出召开董事会定期会议的通 ...

Summary of Key Points Core Viewpoint - The company Zhejiang Haizheng Biomaterials Co., Ltd. is experiencing stock fluctuations, with a recent decline in share price and ongoing shareholder activities including share buybacks and planned reductions in holdings by major shareholders [1][2]. Group 1: Stock Performance - As of July 4, 2025, the stock price of Haizheng Biomaterials closed at 12.06 yuan, down 4.96% from the previous week [1]. - The stock reached a high of 12.86 yuan and a low of 11.85 yuan during the week [1]. - The current market capitalization is 2.444 billion yuan, ranking 62nd in the plastics sector and 4703rd in the A-share market [1]. Group 2: Shareholder Activities - Sinopec Capital, a major shareholder, holds 13,659,494 shares (6.74% of total shares) and plans to reduce its holdings by up to 3,525,600 shares (1.74% of total shares) through block trading within three months from the announcement date [1][3]. - In the past 12 months, Sinopec Capital has already reduced its holdings by 2,026,780 shares (1% of total shares) at prices ranging from 10.17 to 12.02 yuan per share [1]. Group 3: Share Buyback Progress - The company has initiated a share buyback program with a budget of 20 million to 30 million yuan, aimed at employee stock ownership plans or equity incentives [2]. - As of June 30, 2025, the company has repurchased 1,482,364 shares, representing 0.731% of total shares, with a total expenditure of approximately 14.29 million yuan [2].

证券代码：688203 证券简称：海正生材 公告编号：2025-36 浙江海正生物材料股份有限公司 重要内容提示： | 回购方案首次披露日 | 2024/8/29 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 月 28 8 月 | 8 | 日~2025 | 年 | 27 | 日 | | 预计回购金额 | 2,000万元~3,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 1,482,364股 | | | | | | | 累计已回购股数占总股本比例 | 0.731% | | | | | | | 累计已回购金额 | 14,288,602.36元 | | | | | | | 实际回购价格区间 | 7.76元/股~10.53元/股 | | | | | | 一、回购股份的基本情况 浙江海正生物材料股份有限 ...

Group 1 - Aike Cyber (688719.SH) shareholders Dachen Chuangtong and Dachen Chuanghong reduced their holdings by 2,298,151 shares, accounting for 1.99% of the total share capital, and did not complete the planned reduction [1] - Benchuan Intelligent (300964.SZ) controlling shareholder Dong Xiaojun reduced his holdings by 355,787 shares, accounting for 0.4582% of the total share capital, bringing his shareholding down to 21.64% [1] - Changlian Co., Ltd. (603648.SH) completed its reduction plan by selling 3,624,050 shares, which is 1% of the total share capital [1] Group 2 - Chuan Yi Technology (002866.SZ) controlling shareholder Zou Weimin and his concerted party reduced their holdings, with Zou's shareholding dropping to 48.53% [2] - Daoshi Technology (300409.SZ) controlling shareholder Rong Jihua plans to reduce his holdings by up to 15,416,611 shares, accounting for 1.97% of the total share capital [2] - Electric Alloy (300697.SZ) completed its reduction plan by selling 2,741,390 shares, which is 0.63% of the total share capital [2] Group 3 - Fujirei (688272.SH) shareholders Suzhou Kongkong, Suzhou Zhaorong, and Shanghai Zhaoren reduced their holdings by 1,215,618 shares, 1,463,490 shares, and 44,944 shares, accounting for 1.60%, 1.93%, and 0.06% of the total share capital respectively [3] - Gaoweida (300465.SZ) controlling shareholder Yingtan Yinggao Investment Consulting Co., Ltd. reduced its holdings by 4,261,700 shares, accounting for 0.96% of the total share capital, bringing its shareholding down to 22.00% [3] - Haizheng Materials (688203.SH) shareholder Sinopec Capital plans to reduce its holdings by up to 3,525,600 shares, accounting for 1.74% of the total share capital [3] Group 4 - Hangyu Micro (300053.SZ) shareholder Yan Jun reduced his holdings by 3,930,000 shares, accounting for 0.56% of the total share capital [4] - He Shi Eye Hospital (301103.SZ) shareholder Advanced Manufacturing Industry Investment Fund plans to reduce its holdings by up to 3,106,074 shares, accounting for 2% of the total share capital [4] - He Yuan Gas (002971.SZ) shareholder Baishide Chuangye completed its reduction plan by selling 854,064 shares, which is 0.415% of the total share capital [4] Group 5 - Huaren Health (301408.SZ) shareholder Saifu Investment reduced its holdings by 2,107,696 shares, accounting for 0.53% of the total share capital [5] - Jiangsu Boyun (301003.SZ) shareholder Gong Wei reduced his holdings by 1,558,900 shares, accounting for 1.57% of the total share capital [5] - Jeya Co., Ltd. (301108.SZ) shareholders Mingyuan Fund and its concerted party did not reduce their holdings, and the reduction plan period expired [5] Group 6 - Longxin General (603766.SH) directors plan to reduce their holdings by up to 350,000 shares and 100,000 shares, accounting for 0.0170% and 0.0049% of the total share capital respectively [6] - Ruchuang Micro-Nano (688002.SH) shareholder Li Weicheng plans to reduce his holdings by up to 8,000,000 shares, accounting for 1.75% of the total share capital [6] - Shilan Micro (600460.SH) shareholder Luo Huabing plans to reduce his holdings by up to 500,000 shares, accounting for 0.03005% of the total share capital [6] Group 7 - Tongfu Microelectronics (002156.SZ) shareholder National Integrated Circuit Industry Investment Fund reduced its holdings by 15,175,969 shares, accounting for 1% of the total share capital [7] - Wangzi New Materials (002735.SZ) controlling shareholder Wang Jinjun reduced his holdings by 9,717,874 shares, accounting for 2.54% of the total share capital [7] - Xingye Co., Ltd. (603928.SH) shareholder Shen Genzhen reduced his holdings by 2,620,000 shares, accounting for 1.00% of the total share capital [7] Group 8 - Yikang Co., Ltd. (301085.SZ) controlling shareholder concerted party reduced its holdings by 633,700 shares, accounting for 0.73% of the total share capital [8] Group 9 - Yiming Pharmaceutical (002826.SZ) major shareholder Zhou Zhan reduced his holdings by 3,586,777 shares, accounting for 1.88% of the total share capital [9] - Yiming Pharmaceutical (002826.SZ) director Xi Ke reduced his holdings by 283,862 shares, accounting for 0.15% of the total share capital [9] - Youyan Powder Materials (688456.SH) concerted party reduced its holdings by 1,030,000 shares, accounting for 0.99% of the total share capital [9] Group 10 - Zhongma Transmission (603767.SH) directors plan to reduce their holdings through block trading and centralized bidding [10] - Zhongqi Co., Ltd. (301215.SZ) shareholder Jiangsu Yueda Group did not reduce its holdings, and the reduction plan period expired [10]

Core Viewpoint - As of June 30, 2025, Zhejiang Haizheng Biomaterials Co., Ltd. (海正生材) reported a closing price of 12.66 yuan, reflecting a decrease of 0.24% with a turnover rate of 5.89% and a trading volume of 69,300 shares, amounting to a transaction value of 87.1 million yuan [1]. Trading Information Summary - On June 30, 2025, the fund flow for Haizheng Biomaterials was as follows: - Net outflow of main funds was 14.64 million yuan, accounting for 16.81% of the total transaction value - Net inflow of retail funds was 11.67 million yuan, representing 13.39% of the total transaction value - Net inflow of speculative funds was 2.97 million yuan, making up 3.41% of the total transaction value [2][4]. Company Announcement Summary - Zhejiang Haizheng Biomaterials announced a shareholder reduction plan: - As of the announcement date, Sinopec Capital held 13,659,494 shares, representing 6.74% of the total share capital - Sinopec Capital plans to reduce up to 3,525,600 shares within three months through block trading, which is no more than 1.74% of the total share capital, with the reduction price determined by market conditions - In the past 12 months, Sinopec Capital has reduced 2,026,780 shares, accounting for 1% of the total share capital, with a reduction price range of 10.17 to 12.02 yuan per share - Sinopec Capital has committed not to transfer or manage the shares held prior to the public offering for 12 months post-listing or three years after completing the business registration [2][4].

Core Viewpoint - The major shareholder, Sinopec Capital, plans to reduce its stake in Zhejiang Haizheng Biomaterials Co., Ltd. due to funding needs for business development, intending to sell up to 3,525,600 shares, which represents no more than 1.74% of the total share capital [1][2]. Group 1: Shareholder Information - Sinopec Capital holds 13,659,494 shares, accounting for 6.74% of the total share capital of the company [1][2]. - The shares held by Sinopec Capital were acquired before the company's initial public offering (IPO) and became tradable on February 19, 2024 [1][2]. Group 2: Reduction Plan Details - The reduction plan allows Sinopec Capital to sell up to 3,525,600 shares within three months starting from fifteen trading days after the announcement [1][2]. - The selling price will be determined based on the market price at the time of the sale [1][2]. - If there are any changes in the company's total share capital due to stock dividends, capital increases, or other corporate actions, the number of shares to be reduced will be adjusted accordingly [1][2]. Group 3: Compliance and Commitments - Sinopec Capital has committed to not transferring or managing the shares held prior to the IPO for a period of twelve months from the listing date or three years from the date of share acquisition, whichever is later [3][4]. - The shareholder will comply with relevant laws and regulations during the reduction process and will ensure timely disclosure of information [4][5].